GENE ONLINE|News &
Opinion
Blog

2024-11-26| Asia Pacific

PuriBlood Breaks into Brazil: Partners with ABHH and Cromo to Conquer Latin America’s Largest Blood Market

by Bernice Lottering
Share To
PuriBlood Expands into Brazil on 11/25 with Clinical and Sales Agreement Signing

PuriBlood (TPEX: 6847), a Taiwanese biotech company, specializes in developing and producing Taiwan’s only domestic leukocyte filter blood bags. It officially signed two cooperation agreements with the Brazilian Association of Hematology, Hemotherapy, and Cell Therapy (ABHH) and Cromo Comercio and Distribuicao de Materiais Odonto-Medico Hospitlares Ltda. (Cromo). Guests from the Taiwan External Trade Development Council (TAITRA) and others witnessed the agreements. This marks PuriBlood’s official entry into Brazil, the largest blood market in South America. It also sets a new milestone for Taiwanese medical and blood research technology in the country.

PuriBlood signs clinical and sales agreements with Brazil’s ABHH Association and Cromo Company, marking its entry into the largest blood market in Central and South America. Pictured (from left to right): ABHH Chairman Dante Langhi, PuriBlood Chairman Chen Yan-Wen, and Cromo Company Chairman Shi Mingqi (石明啟). Image courtesy of PuriBlood.

PuriBlood’s Innovations: Real-Time Leukocyte Reduction and High Platelet Recovery for Advanced Blood Processing

PuriBlood’s Chairman, Chen Yan-Wen, announced that Brazil is the first major single-market that PuriBlood has entered globally, with demand surpassing that of Taiwan. Brazil serves not only as a key gateway to Central and South America, but also provides a clinical and medical system modeled after the American system. Consequently, this will lay the groundwork for PuriBlood’s future entry into the European and American markets. Through Cromo, the company plans to expand its product sales to blood bank groups like the Pulsa group and large hospitals.

Additionally, in the newly signed agreement, ABHH will collaborate with PuriBlood to conduct clinical research on the Real-Time Leukocyte Reduction Filter and High Platelet Recovery Whole Blood Filter. ABHH Chairman Dante Langhi emphasized that all existing leukocyte reduction products in the market focus on blood storage at blood banks. However, PuriBlood’s Real-Time System, designed to simultaneously reduce leukocytes during blood donation, revolutionizes traditional processes. ABHH is proud to partner with PuriBlood during the clinical trial phase, aiming to create a new future.

PuriBlood Enters the Largest Blood Market in Central and South America, Signing Clinical and Sales Agreements with Brazil’s ABHH Association and Cromo Company

Cromo Company Chairman, Shi Mingqi (石明啟), highlighted that Taiwan’s blood donation rate ranks among the top globally at 8%. Taiwan produces approximately 1.8 million blood bags annually. In contrast, Brazil’s market produces 5 to 6 million blood bags per year. With policy promotion, Brazil’s market shows potential for growth. Shi believes that PuriBlood’s leukocyte reduction filter, with its superior performance, will deliver impressive results in Brazil.

The ABHH association includes over 4,000 members. It is a national federation of professionals in hematology, hemotherapy, and cell therapy. ABHH promotes cell and gene therapies, including CAR-T therapies for blood cancers. Furthermore, it collaborates with Brazil’s National Health Regulatory Agency (Anvisa) to regulate the development of cell therapies and ensure that new technologies can be applied in clinical settings.

Cromo, based in São Paulo, specializes in distributing medical, dental, and healthcare equipment. It supplies hospitals, laboratories, and surgical operations with necessary instruments and materials.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Shared Expertise, Shared Vision: Biotech Powerhouses Drive Innovation in This Billion-Dollar Market
2024-11-27
Taiwan and Australia Bridge Biotech Frontiers and Strengthen Ties at AusBiotech 2024
2024-11-14
Illumina Stepping It Up in Gene Sequencing Innovation with Global Launch of New Tech—MiSeq i100 Series in Taipei
2024-10-16
LATEST
How FIRM is Shaping Regenerative Medicine in Japan
2024-12-09
AI, Smart Tech, and ICT to Unite the Global Biotech and Healthcare Industries in 2025
2024-12-06
Core8 Group to Establish Vietnam’s First Comprehensive Biotechnology Incubator
2024-12-05
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
2024-12-05
Ipsen Bets $600M on Biomunex’s First-in-Class T-Cell Engager BMX-502
2024-12-03
Gilead Strikes Again: $415M Bet on ADCs with Tubulis Deal
2024-12-03
FDA Investigates Reports of Blood Cancer Cases Linked to Gene Therapy
2024-12-02
EVENT
Scroll to Top